Literature DB >> 24696065

Bitopertin: the good news and bad news.

Donald C Goff1.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24696065     DOI: 10.1001/jamapsychiatry.2014.257

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


× No keyword cloud information.
  9 in total

Review 1.  The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.

Authors:  Samuel M Cohen; Richard W Tsien; Donald C Goff; Michael M Halassa
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

2.  Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.

Authors:  Deepak Cyril D'Souza; Richard E Carson; Naomi Driesen; Jason Johannesen; Mohini Ranganathan; John H Krystal
Journal:  Biol Psychiatry       Date:  2018-01-31       Impact factor: 13.382

Review 3.  Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropharmacology       Date:  2019-05-08       Impact factor: 5.250

Review 4.  Computational psychiatry.

Authors:  Xiao-Jing Wang; John H Krystal
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

Review 5.  SLC transporters as therapeutic targets: emerging opportunities.

Authors:  Lawrence Lin; Sook Wah Yee; Richard B Kim; Kathleen M Giacomini
Journal:  Nat Rev Drug Discov       Date:  2015-06-26       Impact factor: 84.694

6.  Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene.

Authors:  J Alexander Bodkin; Michael J Coleman; Laura J Godfrey; Claudia M B Carvalho; Charity J Morgan; Raymond F Suckow; Thea Anderson; Dost Öngür; Marc J Kaufman; Kathryn E Lewandowski; Arthur J Siegel; Elliot Waldstreicher; Christopher M Grochowski; Daniel C Javitt; Dan Rujescu; Scott Hebbring; Richard Weinshilboum; Stephanie Burgos Rodriguez; Colette Kirchhoff; Timothy Visscher; Alexander Vuckovic; Allison Fialkowski; Shane McCarthy; Dheeraj Malhotra; Jonathan Sebat; Donald C Goff; James I Hudson; James R Lupski; Joseph T Coyle; Uwe Rudolph; Deborah L Levy
Journal:  Biol Psychiatry       Date:  2019-05-09       Impact factor: 13.382

7.  Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.

Authors:  Robert A McCutcheon; John H Krystal; Oliver D Howes
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

Review 8.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

Review 9.  D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.

Authors:  Donald C Goff
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.